FOLH1 and neoplasm: In a phase I trial Milowsky et al. demonstrated that tumor-associated neovasculature in multiple advanced metastatic solid cancers could be targeted with an Indium-111- labeled antibody (J591) binding the extracellular domain of PSMA.